## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%); PEG 1.07 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($199.96)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. J&J’s ‘remarkable’ Tecvayli data support earlier use in multiple myeloma**
- Source: BioPharma Dive | 20251209T130817 | Bullish | Relevance: 99%
-  New data from Johnson & Johnson's MajesTEC-3 trial suggest that a Tecvayli-based combination therapy could offer a curative potential when used early in the treatment of multiple myeloma. The combination of Tecvayli with Darzalex significantly reduced the risk of disease progression or death by 83% and led to an 82% complete response rate, compared to standard treatments. This positive outcome points to a future where bispecific antibodies like Tecvayli could be moved to earlier lines of care, offering a more accessible alternative to CAR-T therapies, though vigilance regarding infection risks remains crucial.

**2. Axa S.A. Raises Stake in Johnson & Johnson $JNJ**
- Source: MarketBeat | 20251209T083129 | Bullish | Relevance: 99%
-  Axa S.A. increased its stake in Johnson & Johnson (NYSE:JNJ) by 1.0% in the second quarter, bringing its total holdings to 803,954 shares valued at $122.8 million. Other institutional investors also adjusted their positions in JNJ. Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, and analysts rate the stock a "Moderate Buy" with an average target price of $203.15.

**3. Early use of CARVYKTI shows lasting remissions in multiple myeloma**
- Source: PharmaTimes | 20251208T140824 | Bullish | Relevance: 99%
- Johnson & Johnson has released updated results from the phase 3 CARTITUDE-4 study, indicating that CARVYKTI (cilta-cel) can achieve durable, treatment-free remissions in relapsed or refractory multiple myeloma patients as early as second-line therapy. The study showed that 80% of standard-risk patients treated with cilta-cel after first relapse remained progression and treatment-free at 2.5 years. These findings support the potential for cilta-cel to fundamentally shift the trajectory of multiple myeloma and extend patients' lives.

**4. Texas AG Secures Restraining Order Against J&J, Kenvue Over Alleged Business Registration Violations**
- Source: Dallas Express | 20251208T175324 | Neutral | Relevance: 99%
-  Texas Attorney General Ken Paxton has secured a temporary restraining order against Johnson & Johnson and Kenvue Inc. for allegedly failing to register their businesses in Texas, a violation of state law. Johnson & Johnson's registration has lapsed, while Kenvue and Kenvue Brands LLC have never registered despite extensive operations in the state. A hearing is set for December 15, 2025, to determine if the companies must cease Texas operations if they remain non-compliant.

**5. ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma**
- Source: Fierce Pharma | 20251209T120837 | Bullish | Relevance: 99%
-  Johnson & Johnson presented positive Phase 3 MajesTEC-3 trial data for its Tecvayli-Darzalex combination in multiple myeloma patients, showing an 83% reduction in progression or death risk. This regimen, which significantly improved overall survival, could be a strong alternative to CAR T-cell therapies like J&J’s own Carvykti, especially for patients who cannot access CAR-T in community settings. The data suggests potential competition for existing CAR-T treatments and highlights J&J's efforts to expand Tecvayli's role in earlier lines of therapy.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Guggenheim | $227 | $206 | +10% |
| 2025-12-02 | Barclays | $197 | $176 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Guggenheim | main | Buy |
| 2025-12-02 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.26M) |
| Sells | 7 ($4.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Insider selling cluster: $4.1M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.07 suggests fair value with growth premium. Forward P/E 17.9x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (2 raises, avg +11%). Insider selling cluster ($4.1M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $497.6B |
| Beta | 0.35 |
| 52W Range | $140.68 - $207.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.07 |
| Forward P/E | 17.9 |
| Current P/E | 19.0 |
| YoY Growth | 6.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.1% to 0.2% (+3.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 at 1.6% confirms short-term momentum alignment. Outperforming sector by 3.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.63), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.25% (CS: 53) | Neutral |
| RSI_14 | 66.7 | Neutral |
| MACD Histogram | -0.63 | Bearish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.209x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $206.54
- **Stop Loss:** $199.96 (3.2% risk)
- **Target:** $213.12 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 75
- **Position Value:** $15,490.50
- **Portfolio %:** 15.49%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*